Expression levels of FGFR3 as a prognostic marker for the progression of primary pT1 bladder cancer and its association with mutation status

The present study examined the utility of fibroblast growth factor receptor 3 (FGFR3) mutation status and gene expression as a prognostic marker in primary pT1 bladder cancer (BC). A total of 120 patients with primary pT1 BC were enrolled. FGFR3 mutation status was determined by direct sequencing an...

Full description

Saved in:
Bibliographic Details
Published in:Oncology letters 2017-09, Vol.14 (3), p.3817-3824
Main Authors: Kang, Ho Won, Kim, Ye-Hwan, Jeong, Pildu, Park, Cheol, Kim, Won Tae, Ryu, Dong Hee, Cha, Eun-Jong, Ha, Yun-Sok, Kim, Tae-Hwan, Kwon, Tae Gyun, Moon, Sung-Kwon, Choi, Yung Hyun, Yun, Seok-Joong, Kim, Wun-Jae
Format: Article
Language:English
Subjects:
Bladder cancer
Care and treatment
Clinical medicine
Development and progression
expression
Females
fibroblast growth factor receptor 3
Fibroblast growth factor receptors
Fibroblasts
Gender
Gene expression
Gene mutation
Genetic aspects
Growth factors
Health aspects
Kinases
Medical prognosis
Metastasis
Multivariate analysis
Mutation
Oncology
Patients
prognosis
Rodents
Standard deviation
Studies
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The present study examined the utility of fibroblast growth factor receptor 3 (FGFR3) mutation status and gene expression as a prognostic marker in primary pT1 bladder cancer (BC). A total of 120 patients with primary pT1 BC were enrolled. FGFR3 mutation status was determined by direct sequencing and FGFR3 mRNA expression level was determined by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis. The results were compared with the clinicopathological parameters, and the prognostic value of FGFR3 was evaluated by Kaplan-Meier analysis and a multivariate Cox regression test. FGFR3 mutations were identified in 48/120 (40.0%) patients with pT1 BC. FGFR3 mRNA expression level was significantly higher in those with BC harboring FGFR3 mutations (P
ISSN:1792-1074
1792-1082
DOI:10.3892/ol.2017.6621